Employees: 1,723
Size HK inno.N (195940.KS) is a South Korea Health Care company (Medical/Nursing Services) with a market value of $783M, the 275th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩36,400 on 18 Nov 2026.
Performance Over six months the shares fell 28.1%, against +0.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +4.1%); the operating margin is 11.9% (peer median 6.8%).
Valuation It trades at 12.3× forward earnings against a peer median of 19.8× (7th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points above its cost of capital (5.4% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.08T | ₩1.06T | ₩897B | ₩829B | ₩847B |
| Revenue growth | — | +19% | +8% | -2% | — |
| Gross profit | ₩480B | ₩472B | ₩414B | ₩355B | ₩333B |
| EBITDA | ₩174B | ₩156B | ₩130B | ₩101B | ₩87.1B |
| Net income | ₩86.9B | ₩75.7B | ₩61.6B | ₩47.2B | ₩38.1B |
| Free cash flow | ₩93.4B | ₩73.2B | -₩25.9B | ₩32.4B | ₩26.7B |
| Capital expenditure | ₩47.0B | ₩86.3B | ₩126B | ₩39.1B | ₩22.9B |
| Total debt | ₩467B | ₩522B | ₩439B | ₩451B | ₩457B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 195940.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | +1.0% | 6th highest of 21 |
| 6-month return | -28.1% | +0.9% | 2nd lowest of 21 |
| Distance from 52-week high | -37.9% | -24.0% | 6th lowest of 21 |
| Revenue growth (TTM) | +7.1% | +4.1% | 8th highest of 21 |
| Operating margin | 11.9% | 6.8% | 8th highest of 21 |
| Forward P/E | 12.3× | 19.8× | 7th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -4.7% | 10.1% | 5th least demanding of 18 |
| Growth delivered (Del g) | +12.2% | +10.9% | 9th highest of 18 |
| Hurdle (Req g minus delivered) | -16.8 pp | -1.1 pp | 3rd least demanding of 18 |
| ROIC minus cost of capital | +0.2 pp | -0.3 pp | 10th highest of 20 |
| EV / EBITDA | 7.8× | 9.2× | 7th cheapest of 16 |
| Net debt / EBITDA | 1.9× | 2.0× | 8th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 12.3× | -4.7% | +12.2% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |